EUVIMEDEUVIMED entdecken
Fall-Kontroll-Studie

Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study

Yinan Huang, Sandeep K Agarwal, Satabdi Chatterjee, Hua Chen, Michael L Johnson, Rajender R Aparasu

Clinical Rheumatology · 2024

DOI: 10.1007/s10067-023-06709-2 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Clinical Rheumatology, 2024. Verfasst von Yinan Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Administration, College of Pharmacy, University of Mississippi, Oxford, MS, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study examined the risk of cardiovascular disease (CVD) associated with the disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA). METHOD: This nested case-control study used the MarketScan database (2012-2014), involving adult RA patients (aged ≥18 years) initiating either a conventional synthetic (cs) DMARD, biologic DMARD, or targeted synthetic (ts) DMARD between January 1, 2013 and December 31, 2014 (cohort entry) and had no CVD history. Cases were individuals with incident CVD identified using diagnosis codes or procedure codes from medical claims. For each case, 10 age- and sex-matched controls were selected using the incident density sampling with replacement. Prescriptions of DMARDs were measured 90 days before the event date. Conditional logistic regression examined the association of risk of CVD with DMARDs in combination treatment or individual use, with reference to methotrexate (MTX) monotherapy, adjusting for baseline confounders. Subgroup analyses were performed separately in DMARD combination therapy users or individual DMARD users, respectively. RESULTS: In total, 270 cases of incident CVD and 2700 controls were included (mean [standard deviation (SD)] age: 54 [1]; 75.6% women). The commonly prescribed DMARD therapies were csDMARD monotherapy (n = 795, 27.04%), followed by tumor necrosis factor inhibitors (TNFi) monotherapy (n = 367, 12.48%), and TNFi in combination with MTX (n = 314, 10.68%). Compared with MTX monotherapy, overall use of DMARD agents was not associated with the differential risk of CVD, including various types of DMARD combination regimens. The findings were similar across subgroup analyses. CONCLUSIONS: The study found no differential risk of CVD with DMARDs in combination therapy or monotherapy compared to MTX monotherapy in patients with RA. Key Points • This study evaluated the risk of cardiovascular disease (CVD) associated with the disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA). • Findings suggest no differential CVD risk with DMARDs in combination with MTX or used individually compared with MTX monotherapy in patients with early RA. • Further efforts should focus on a better understanding of the mechanism of DMARD combination treatments with MTX in modifying CV risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesAntirheumatic AgentsArthritis, RheumatoidAdultHumansFemaleAdolescentMiddle AgedMaleCase-Control StudiesMethotrexateDrug Therapy, CombinationTumor Necrosis Factor InhibitorsTreatment Outcome

Stichwörter der Autor:innen

Cardiovascular riskConventional synthetic disease-modifying anti-rheumatic drugsNested case-control studyNon-TNFi biologicsRheumatoid arthritisTNF-α inhibitors

Substanzen

Antirheumatic AgentsMethotrexateTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy Administration, College of Pharmacy, University of Mississippi, Oxford, MS, USA.
  • Section of Immunology, Allergy & Rheumatology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, 4849 Calhoun Road, Health & Sciences Bldg. 2, Houston, TX, 77204, USA.
  • Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, 4849 Calhoun Road, Health & Sciences Bldg. 2, Houston, TX, 77204, USA. rraparasu@uh.edu.

Zitieren

APA

Huang, Y., Agarwal, S. K., Chatterjee, S., Chen, H., Johnson, M. L., & Aparasu, R. R. (2024). Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study. Clinical Rheumatology. https://doi.org/10.1007/s10067-023-06709-2

Vancouver

Huang Y, Agarwal SK, Chatterjee S, Chen H, Johnson ML, Aparasu RR. Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study. Clinical Rheumatology. 2024. doi:10.1007/s10067-023-06709-2

BibTeX
@article{Huang2024,
  author = {Huang, Yinan and Agarwal, Sandeep K and Chatterjee, Satabdi and Chen, Hua and Johnson, Michael L and Aparasu, Rajender R},
  title = {Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study},
  journal = {Clinical Rheumatology},
  year = {2024},
  doi = {10.1007/s10067-023-06709-2}
}
Kostenlos starten →